Company intelligence / Profile preview

AngioDynamics

Latham, New York, United Stateslinkedin.com ↗

Ownership: Public · ANGO
Employees: ~1200
Development stage: Phase 2

Overview

Recent clinical results include the APEX-AV trial for the AlphaVac F18 85 System, which demonstrated safety and efficacy in treating patients with pulmonary embolism. The trial showed a decrease of 0.45 in the RV/LV ratio at 48 hours, surpassing the expected improvement of 0.12, with major adverse events occurring in only 4.1% of cases compared to the expected 25%[8].

Therapeutic areas: OncologyCardiovascular
Modalities: Minimally invasive medical devices
Industry: Surgical Medical Devices

Drug pipeline

3 assets

AlphaVac F18 85 System

Phase 2

Indications: Pulmonary embolism

2 more assets in the full pipeline.

Request access →

Partnerships

Pulmonary Embolism Response Team (PERT) Consortium

Financials

Market cap: $629.1M
Total revenue: $86.6M
Enterprise value: $575.2M

Beyond the preview

Go deeper on AngioDynamics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AngioDynamics.

Explore the full profile